References of "Petermans, Jean"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSarcopenia as a public health problem
Bruyère, Olivier ULg; Beaudart, Charlotte ULg; Locquet, Médéa ULg et al

in European Geriatric Medicine (2015)

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an ... [more ▼]

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an effective treatment. In this paper, we review the main current literature on sarcopenia in order to assess whether this geriatric syndrome could be considered as a major public health problem. Our review highlights that based on its prevalence, its clinical consequences, the limitations of the current available treatments as well as on the fact that many frail patients are affected by this geriatric syndrome, sarcopenia should be considered as a health priority by all interested parties in order to reduce its burden. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailQualité de vie du patient sarcopénique : apport de l’étude liégeoise SarcoPhAge
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; PETERMANS, Jean ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2015), 13(4), 391-5

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic ... [more ▼]

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic quality of life questionnaires such as SF36 and EQ5D. The SarcoPhAge study, conducted on a cohort developed in Liège including 534 subjects of 65 years or older, suggested that sarcopenic subjects present a significant worse quality of life in the domains of physical function compared to nonsarcopenic subjects. Generic tools do not cover exhaustively all the areas of potential dysfunction concerned in this geriatric syndrome. Yet, there is no specific and validated quality of life questionnaire for sarcopenia. It would be useful to have at our disposal a sarcopenia specific quality of life questionnaire to assess not only the prospective quality of life of sarcopenic subjects but also to assess the efficacy and the rele [less ▲]

Detailed reference viewed: 15 (8 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient contents of food served and consumed by nursing home residents
Buckinx, Fanny ULg; Paquot, Nicolas ULg; Allepaerts, Sophie ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailImpact of the frailty status on muscle mass and muscle strength of nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailCorrelation between muscle mass and muscle strength among nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQol
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Rizzoli, R. et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailQuality of life and physical components linked to sarcopenia: baseline data of the SarcoPhAge study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 30 (5 ULg)
Full Text
Peer Reviewed
See detailAGAINST AGE DISCRIMATION
STRANDBERG, TIMO; MAGGI, STEFANIA; HARKIN, MARIAN et al

in Lancet (2015), 386

Detailed reference viewed: 36 (8 ULg)
Full Text
See detailOxidative stress or not in healthy older subjects?
PINCEMAIL, Joël ULg; CHRISTELBACH, Sophie ULg; RICOUR, Céline ULg et al

in OCC2015 (2015, June)

Detailed reference viewed: 31 (14 ULg)
Full Text
See detailCholestérol haut, cholestérol bas: quels sont les risques en gériatrie ?
ANCION, Arnaud ULg; PAQUOT, Nicolas ULg; BOLAND, BENOIT et al

Scientific conference (2015, March 19)

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailEtude GEROX : Evaluation du statut de stress oxydant
CHRISTELBACH, SOPHIE; RICOUR, Céline ULg; Dardenne, Nadia ULg et al

Poster (2015, March)

Detailed reference viewed: 28 (3 ULg)
See detailLe syndrome dysexécutif pour les nuls
Adam, Stéphane; SALMON, Eric ULg; GILLAIN, Sophie ULg et al

Conference (2015, January 15)

Detailed reference viewed: 36 (3 ULg)
Full Text
See detailTreatment of pneumonia in demented patients
ALLEPAERTS, Sophie ULg; PETERMANS, Jean ULg

Learning material (2015)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailEstimation of sarcopenia prevalence using various assessment tools
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Experimental Gerontology (2015), 61

BACKGROUND: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the ... [more ▼]

BACKGROUND: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the diagnostic tools that have to be used. In this study, we compared the prevalence of sarcopenia assessed using different diagnostic tools. METHODS: To measure muscle mass, muscle strength and physical performance, we used for each outcome two different diagnostic tools. For muscle mass, we used Dual Energy X-Ray Absorptiometry (DXA) and bio-electrical impedance analysis (BIA); for muscle strength, we used a hydraulic dynamometer and a pneumatic dynamometer; for physical performance we used the Short Physical Performance Battery test (SPPB test) and the walk speed. Eight diagnostic groups were hereby established. RESULTS: A total of 250 consecutive subjects were recruited in an outpatient clinic in Liège, Belgium. Estimated prevalence of sarcopenia varied from 8.4% to 27.6% depending on the method of diagnosis used. Regarding muscle mass, BIA systematically overestimated muscle mass compared to DXA (mean estimated prevalence with BIA=12.8%; mean prevalence with DXA=21%). For muscle strength, the pneumatic dynamometer diagnosed twice more sarcopenic subjects than the hydraulic dynamometer (mean estimated prevalence with PD=22.4%; mean estimated prevalence with HD=11.4%). Finally, no difference in prevalence was observed when the walking speed or the SPPB test was used. A weak overall kappa coefficient was observed (0.53), suggesting that the 8 methods of diagnosis are moderately concordant. CONCLUSION: Within the same definition of sarcopenia, prevalence of sarcopenia is highly dependent on the diagnostic tools used. [less ▲]

Detailed reference viewed: 61 (35 ULg)
Full Text
Peer Reviewed
See detailQuality of life and physical components linked to sarcopenia: The SarcoPhAge study.
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Experimental gerontology (2015), 69

INTRODUCTION: The SarcoPhAge project is an ongoing longitudinal study following community-dwelling elderly subjects with the objective to assess some health and functional consequences of sarcopenia. The ... [more ▼]

INTRODUCTION: The SarcoPhAge project is an ongoing longitudinal study following community-dwelling elderly subjects with the objective to assess some health and functional consequences of sarcopenia. The sarcopenia diagnosis algorithm developed by the European Working Group on Sarcopenia in Older People (EWGSOP) and used in the present study needs further validation through cross-sectional and longitudinal studies. The aim of the present study is to assess, using this algorithm, the prevalence of sarcopenia and the clinical components linked to this geriatric syndrome. METHODS: Participants were community dwelling subjects aged 65years or older. To diagnose sarcopenia, we applied the definition of the EWGSOP. Muscle mass was measured by dual-energy X-ray absorptiometry, muscle strength by a hydraulic dynamometer and physical performance by the SPPB test. Large amounts of socio-demographic, anamnestic and clinical data were collected in all subjects. RESULTS OVER ONE YEAR: 534 subjects were recruited for this study (60.5% of women, mean age of 73.5+/-6.16years), among whom 73 subjects were diagnosed sarcopenic, which represents a global prevalence of 13.7%. Prevalence was 11.8% in men and 14.9% in women. Sarcopenic subjects were older; had a lower Body Mass Index, lower calf, waist, wrist and arm circumferences; presented more cognitive impairments (Mini-Mental State Examination), more comorbidities; were more often malnourished; and consumed more drugs. After adjustment for age, BMI, cognitive status, nutritional status, number of comorbidities and number of drugs, sarcopenic subjects had a worse physical health-related quality of life (SF-36) for the domain of physical functioning, were at higher risk of falls (Timed Up and Go test), were more frail (Fried), presented more often tiredness for the achievement of activities of daily living (Mobility-test), presented less fat mass and obviously less lean mass. Sarcopenic women were also more dependent for housekeeping and handling finances (Lawton scale) than non-sarcopenic ones. CONCLUSION: Sarcopenia seems to be associated with many harmful clinical components making this geriatric syndrome a real public health burden. Follow-up data of the SarcoPhAge study will be helpful to assess the outcomes of sarcopenia based on the EWGSOP diagnosis algorithm and its different proposed cut-offs. [less ▲]

Detailed reference viewed: 97 (41 ULg)